Company intelligence / Profile preview

VoterX

Tucson, Arizona, United Statesvoterx.com ↗

Ownership: Private
Development stage: Other

Overview

Vortex Biotechnology is developing novel small molecule drugs that stimulate RNA degradation to block cancer growth. Their lead compound, VBT-34, is an oral agent being developed for both hematological and solid tumors. The company’s approach is tumor-type agnostic and focuses on first-in-class candidates with compelling biological validation. No clinical results have been published yet; programs are preclinical.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

National Cancer Institute Cancer CentersCollaborations with biopharma companies

Beyond the preview

Go deeper on VoterX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VoterX.

Explore the full profile